Evidence map›Paper›PMID 30159904›Full record

ReviewBioEssays : news and reviews in molecular, cellular and developmental biology2018

TGF-β Control of Adaptive Immune Tolerance: A Break From Treg Cells.

Ming Liu, Shun Li, Ming O Li

Open access · greenAbstract readReview
In one paragraph

Review in BioEssays : news and reviews in molecular, cellular and developmental biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Radiotherapy combined with immunotherapy: the dawn of cancer treatment.Signal transduction and targeted therapy · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ming LiuImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Shun LiImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ming O LiImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Adaptive-Innate Immune Crosstalk in TGF-B Control of Peripheral T Cell ToleranceR01AI122264 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI LI, MING · 2016 to 2020
$2.6M
Howard Hughes Medical InstituteNCI NIH HHS P30 CA008748NIAID NIH HHS R01 AI122264
6 · The paper itself

Abstract

The vertebrate adaptive immune system has well defined functions in maintaining tolerance to self-tissues. Suppression of autoreactive T cells is dependent on the regulatory cytokine transforming growth factor-β (TGF-β) and regulatory T (Treg) cells, a distinct T cell lineage specified by the transcription factor Foxp3. Although TGF-β promotes thymic Treg (tTreg) cell development by repressing T cell clonal deletion and peripheral Treg cell differentiation by inducing Foxp3 expression, a recent study shows that TGF-β suppresses autoreactive T cells independent of Foxp3

Indexed as

Adaptive ImmunityCell DifferentiationHumansImmune ToleranceLymphocyte ActivationT-Lymphocytes, RegulatoryTransforming Growth Factor betaTransforming Growth Factor betaadaptive immunityautoimmunityevolutionFoxp3immune toleranceTGF-βTreg

Identifiers

PMID30159904
PMCPMC6300063
OpenAlexW2889535285

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.